ʻO AffaMed Therapeutics, kahi hui biotechnology pae honua holoʻokoʻa i hoʻolaʻa ʻia i ka hoʻomohala ʻana a me ka hoʻolaha ʻana i nā lāʻau lapaʻau transformative, digital a me nā huahana ʻokiʻoki, i kēia lā ua hoʻolaha ka United States Food and Drug Administration (FDA) i kāna noi Investigational New Drug (IND) no ka hoʻomohala ʻana i ka lāʻau lapaʻau. ʻO AM712 (ASKG712), kahi mole mole biological bispecific proprietary e ālai ana i nā mea ʻelua endothelial growth factor (VEGF) a me ka angiopoietin-2 (Ang-2) no ka mālama ʻana i nā maʻi vascular retinal.
Ma lalo o kēia IND, e hoʻomaka koke ʻo AffaMed i kahi haʻawina Phase 1 ma ʻAmelika Hui Pū ʻIa e noiʻi i ka palekana, ka hoʻomanawanui, pharmacokinetics, a me ka pono o AM712 i nā kumuhana me neovascular AMD.
Ua komo koke ʻo AffaMed Therapeutics i kahi ʻaelike laikini me AskGene Pharma Inc. no nā kuleana kūʻokoʻa e hoʻomohala, hana a kūʻai aku i ka AM712 ma ex-Asia me nā ʻāina ʻo Iapana a puni ka honua.
"Ua hauʻoli mākou e hui pū me AskGene a loaʻa i kā mākou ʻae IND mua mai ka FDA." Ua ʻōlelo ʻo Dr. Dayao Zhao, Luna Nui o AffaMed: "Ma ke ʻano o kā mākou China-for-Global hoʻolālā hoʻolālā e hoʻohana i ka ikaika o AffaMed ma Kina a me ʻAmelika e holomua i nā ʻano lapaʻau like ʻole no nā mākeke honua, ua hoʻoikaika hou kēia palapala laikini i kā mākou ophthalmology pipeline honua. . ʻOliʻoli loa wau i ka ʻike ʻana i kā mākou hoʻokō wikiwiki ʻana i kēia hoʻolālā mai ka laikini ʻana i ka ʻae ʻana o US IND a ke nānā nei i kā mākou pilina pili me AskGene.
"Ua kūpaʻa ʻo AskGene i ka lawe wikiwiki ʻana i nā lāʻau palekana a maikaʻi hoʻi i nā maʻi ma o ka hoʻohana ʻana i nā ʻenehana hou. ʻOliʻoli loa mākou i ka hui pū ʻana me AffaMed e hoʻomohala i ka molekele anti-VEGF/ANG2 bispecific AMG712(ASKG712) e hoʻopōmaikaʻi ai i nā poʻe maʻi" wahi a ka Luna Nui o AskGene ʻo Dr. Jeff Lu: "ʻO ka ʻike kūʻokoʻa honua e ka hui ʻo AffaMed ma ka wahi ophthalmology he noʻonoʻo nui no kā mākou hui pū ʻana. Ke hana pū nei mākou, hiki iā mākou ke hoʻolōʻihi i ka hoʻomohala ʻana o ASKG712 ma ka honua.
Ua ʻōlelo ʻo Dr Ji Li, Pelekikena o AffaMed: "Ke manaʻoʻiʻo nei mākou he hiki i ka AM712 ke hiki ke lilo i molela biological anti-VEGF / Ang-2 bispecific maikaʻi loa e hoʻoponopono i nā pono olakino kiʻekiʻe ʻole i waena o nā maʻi me nā maʻi vascular retinal. Hauʻoli mākou i ka hōʻike ʻana i kā mākou hiki ke hoʻokō ikaika i ka loaʻa ʻana o ka US IND clearance i loko o 2 mau mahina ma hope o ka pau ʻana o kā mākou palapala laikini me AskGene.
